Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes

Treatment options are limited for patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). The recent approval of luspatercept for the treatment of anemia associated with very low-to intermediate-risk MDS with ring sideroblasts (RS) or with myelodysplastic/myeloproliferati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinsley-Vance, Sara M., Davis, Mark, Ajayi, Olalekan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Prescriber's Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894202/
https://www.ncbi.nlm.nih.gov/pubmed/36741213
http://dx.doi.org/10.6004/jadpro.2023.14.1.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894202/
https://www.ncbi.nlm.nih.gov/pubmed/36741213
http://dx.doi.org/10.6004/jadpro.2023.14.1.8

Ejemplares similares